Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.


Related Content

US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators
FDA/EU Mutual Reliance For GMP Inspections Moving Forward
ANDA Supplement Review Timeline Hinges On Need For Inspection
FDA/EMA Bioequivalence Collaboration Is Narrow In Scope, Wide In Reach
Biosimilar User Fee Agreement Includes “Financial Hold” On Development Programs For Failure To Pay
FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
FDA Cloak And Dagger: GMP "Intelligence" Sought As Part Of Globalization Plan
Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts